SCHEMBL563559

SCHEMBL563559

COc1ccc(O)c(-n2nc3ccccc3n2)c1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 6/20 0.64
NPC1 O15118 5/20 0.64
LMNA P02545 3/20 0.64
HTT P42858 1/20 0.56
KMT2A Q03164 4/20 0.46
MEN1 O00255 3/20 0.46
ALDH1A1 P00352 3/20 0.46
SMN1; SMN2 Q16637 3/20 0.46
KDM4E B2RXH2 3/20 0.46
POLB P06746 3/20 0.46
NQO2 P16083 1/20 0.46
MAPT P10636 3/20 0.42
GAA P10253 2/20 0.42
RECQL P46063 2/20 0.42
THRB P10828 1/20 0.42
BLM P54132 1/20 0.42
MCL1 Q07820 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
GUSB P08236 1/20 0.42
ERN1 O75460 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29768260 1.00 RAB9A (0.64) RAB9ANPC1LMNAHTTKMT2A
SCHEMBL9180373 0.87 HTT (0.56) RAB9ANPC1LMNAHTTKMT2A
SCHEMBL29870382 0.87 HTT (0.56) RAB9ANPC1LMNAHTTKMT2A
SCHEMBL564179 0.85 RAB9A (0.61) RAB9ANPC1LMNAHTTKMT2A
SCHEMBL29814623 0.85 RAB9A (0.61) RAB9ANPC1LMNAHTTKMT2A
SCHEMBL11594462 0.84 LMNA (0.49) RAB9ANPC1LMNAHTTKMT2A
SCHEMBL3274618 0.84 NPC1 (0.45) RAB9ANPC1LMNAHTTKMT2A
SCHEMBL11595373 0.83 NPC1 (0.49) RAB9ANPC1LMNAHTTKMT2A
SCHEMBL2806065 0.83 NPC1 (0.59) RAB9ANPC1LMNAHTTKMT2A
SCHEMBL6941182 0.82 RAB9A (0.66) RAB9ANPC1LMNAHTTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 277 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115135307-A Carrier for cell delivery 株式会社ITO 2022-09-30 CN claimed
CN-111057019-A Method for producing 2- (2 '-hydroxy-5' -methoxyphenyl) benzotriazole 吉林师范大学 2020-04-24 CN claimed
EP-1872796-B1 TRANSDERMAL PREPARATION FOR EXTERNAL USE CONTAINING NONSTEROIDAL ANTIINFLAMMATORY/ANALGESIC AGENT HISAMITSU PHARMACEUTICAL CO (JP) 2011-09-21 EP claimed
US-20100311700-A1 Transdermal preparation for external use containing nonsterioidal antiinflammatory/analgesic agent HISAMITSU PHARMACEUTICAL CO., INC. (JP) 2010-12-09 US claimed
US-20080317689-A1 Transdermal Preparation for External Use Containing Antiinflammatory/Analgesic Agent HISAMITSU PHARMACEUTICAL CO., INC. (JP) 2008-12-25 US claimed
EP-1872796-A1 TRANSDERMAL PREPARATION FOR EXTERNAL USE CONTAINING NONSTEROIDAL ANTIINFLAMMATORY/ANALGESIC AGENT HISAMITSU PHARMACEUTICAL CO., INC. (JP) 2008-01-02 EP claimed
US-20070154531-A1 Anti-inflammatory analgesic preparation HISAMITSU PHARMACEUTICAL CO., INC. (JP) 2007-07-05 US claimed
EP-1698330-A1 ANTI-INFLAMMATORY ANALGESIC EXTERNAL PREPARATION HISAMITSU PHARMACEUTICAL CO. INC. (JP) 2006-09-06 EP claimed
US-6201061-B1 CURING A RESIN FOR OPTICAL USE MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) 2001-03-13 US claimed
US-20260117015-A1 METHOD OF CURING A POLYTHIOURETHANE BASED SUBSTRATE WITH A SALT CATALYST ESSILOR INT (FR) 2026-04-30 US disclosed
EP-4495639-B1 OPTICAL MATERIAL DERIVED FROM A POLYMERIZABLE COMPOSITION CONTAINING TERMINAL ALKYNE AND THIOL FUNCTIONS ESSILOR INT (FR) 2026-01-21 EP disclosed
US-20250304740-A1 METHOD OF FAST CURING A POLYTHIOURETHANE BASED SUBSTRATE USING A DELAYED-ACTION CATALYST ESSILOR INTERNATIONAL (FR) 2025-10-02 US disclosed
US-20250295566-A1 DIESTER HAIR STYLING FORMULATIONS, AND USES THEREOF Chembeau LLC 2025-09-25 US disclosed
US-20250248913-A1 HAIR TREATMENT FORMULATIONS AND USES THEREOF Chembeau LLC 2025-08-07 US disclosed
US-4229517-A Dot-etchable photopolymerizable elements E. I. DU PONT DE NEMOURS AND COMPANY (US) 1980-10-21 US disclosed
US-4229520-A Photo-polymerization and development process which produces dot-etchable material E. I. DU PONT DE NEMOURS AND COMPANY (US) 1980-10-21 US disclosed
US-4173673-A Dot-etchable masks from photopolymerizable elements E. I. DU PONT DE NEMOURS AND COMPANY (US) 1979-11-06 US disclosed
US-4126466-A Composite, mask-forming, photohardenable elements E. I. DU PONT DE NEMOURS AND COMPANY (US) 1978-11-21 US disclosed
US-3935164-A NICKEL 3,5-DI-TERT-ALKYL 4-HYDROXYBENZOATE, AND A BENZOPHENONE OR BENZOTRIAZOLE CIBA-GEIGY CORPORATION (US) 1976-01-27 US disclosed
US-3935163-A NICKEL BIS(3,5-DI-TERT-ALKYL-4-HYDROXY BENZOATE AND A BENZOPHENONE OR BENZOTRIAZOLE CIBA-GEIGY CORPORATION (US) 1976-01-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260117015-A1 METHOD OF CURING A POLYTHIOURETHANE BASED SUBSTRATE WITH A SALT CATALYST NCAPH, CTH, CRYAA RAB9A 4139/4885NPC1 457/4885LMNA 186/4885
US-20250295566-A1 DIESTER HAIR STYLING FORMULATIONS, AND USES THEREOF SUCLG1, SMS, SRM RAB9A 4535/4885NPC1 4514/4885LMNA 2295/4885
US-20250248913-A1 HAIR TREATMENT FORMULATIONS AND USES THEREOF FHIT, SUCLG1, TES RAB9A 3197/4885NPC1 4761/4885LMNA 839/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.